The DOI matches its Crossref record.
Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer
Abstract
The phosphatidylinositol 3 kinase (PI3K) pathway is one of the major pathways modulating cell growth, proliferation, metabolism, survival, and angiogenesis. Hyperactivation of this pathway is one of the most frequent occurrences in human cancer and is thus an obvious target for treatment of this disease. Currently there are 26 novel compounds targeting the PI3K pathway being assessed in more than 150 cancer-related clinical trials. Although this pathway is involved in many vital biologic functions, data emanating from these clinical trials indicate that these drugs are well tolerated. This review outlines the interaction of the PI3K pathway with other signaling cascades, highlights mechanisms involved in hyperactivation, discusses current therapeutics in cancer-related clinical trials that target this pathway, and, based on preclinical data, discusses possible leads on patient selection and combinational therapy, including targeting multiple components of the associated signaling network.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
Rangwala, R., Chang, Y. C., Hu, J., Algazy, K. M., Evans, T. L., Fecher, L. A., Schuchter, L. M., Torigian, D. A., Panosian, J. T., Troxel, A. B., et al. (2014) · Autophagy · doi:10.4161/auto.29119 · Cited by 424
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Jiao, Q., Bi, L., Ren, Y., Song, S., Wang, Q., & Wang, Y.-S. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0801-5 · Cited by 395
Phosphatidylinositol 3-phosphates—at the interface between cell signalling and membrane traffic
Marat, A. L., & Haucke, V. (2016) · The EMBO Journal · doi:10.15252/embj.201593564 · Cited by 299
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
Metadata
- Authors
- Sheppard, K., Kinross, K. M., Solomon, B., Pearson, R. B., & Phillips, W. A.
- Venue
- Critical Reviews™ in Oncogenesis
- Publisher
- Begell House
- Published
- 2012
- Volume
- 17
- Issue
- 1
- Pages
- 69-95
- ISSN
- 0893-9675 (ISSN-L)
- OpenAlex
- W2053883587
- Cited by
- 225
- References
- 0
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. https://app.cochat.ai/papers/10.1615/critrevoncog.v17.i1.60
- The paper
- Sheppard, K., Kinross, K. M., Solomon, B., Pearson, R. B., & Phillips, W. A. (2012). Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. Critical Reviews™ in Oncogenesis. https://doi.org/10.1615/critrevoncog.v17.i1.60
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.